Potential conflict of interest: Dr. Asahina is on the speakers' bureau of Chugai Pharma and MSD, and received research funding from Daiichi-Sankyo and Chugai Pharma. Dr. Asahina and Dr. Kakinuma belong to a donation-funded department funded by Chugai Pharma, Toray, Bristol-Myers Squibb, Dainippon-Sumitomo Pharma, and MSD.
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
Article first published online: 19 AUG 2013
Copyright © 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 4, pages 1253–1262, October 2013
How to Cite
Asahina, Y., Tsuchiya, K., Nishimura, T., Muraoka, M., Suzuki, Y., Tamaki, N., Yasui, Y., Hosokawa, T., Ueda, K., Nakanishi, H., Itakura, J., Takahashi, Y., Kurosaki, M., Enomoto, N., Nakagawa, M., Kakinuma, S., Watanabe, M. and Izumi, N. (2013), α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology, 58: 1253–1262. doi: 10.1002/hep.26442
Supported by grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, and the Japanese Ministry of Welfare, Health, and Labor.
- Issue published online: 1 OCT 2013
- Article first published online: 19 AUG 2013
- Accepted manuscript online: 8 APR 2013 04:51AM EST
- Manuscript Accepted: 4 APR 2013
- Manuscript Received: 19 FEB 2013
This article has been cited by:
- 3Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C, Journal of Gastroenterology, 2013,, , , , , , , , , , , , , , , , , ,